Palisade Bio, Inc. (PALI)
Nasdaq · Healthcare · Biotechnology
$1.46+1.39%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $254M
- P/E (trailing)
- 2.4
- 52-week range
- $1.32 – $2.86
- 52-week change
- −24.61%
- EPS (trailing)
- $0.60
- Analyst rating
- 1.1 Strong buy
Fiscal year to Dec 2025
- Revenue
- $0K
- Net income
- −$16.8M
- Diluted EPS
- −$0.30
From the company’s annual report on SEC EDGAR.
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Headquarters: Denver, United States · 14 employees · palisadebio.com